T-DM1 significantly improved progression-free survival in randomized phase II study

ImmunoGen, Inc. (NASDAQ: IMGN), a biotechnology company that develops targeted cancer antibodies based products, today announced that Roche positive top-line results from the first randomised study review Trastuzumab Emtansine (T-DM1,) in HER2 positive metastatic breast cancer (MBC) has disclosed previously known as Trastuzumab-DM1. T-DM1 consists of ImmunoGen's DM1 cancer cell-killing agent connected through the company of linker of HER2-targeting developed antibody Trastuzumab, Genentech, a member of the Roche Group.

The most important results posted by Roche in a press release today were, that of T-DM1 patients is a significant improvement in progression-free survival compared to patients compare with ® Herceptin (trastuzumab) plus chemotherapy (docetaxel) in the phase II trial these agents for first-line treatment for HER2 positive MBC had.

Detailed results from this study randomized, 137 patients are the presentation at a future medical Conference will be submitted. Cheap preliminary data from this study to the 35th Congress of the European society of medical oncology (ESMO) previously reported were, but progression-free survival data not available were disease stages in this

"This top-line information about T-DM1 performance in the first row setting is very encouraging and adds the low efficacy and safety data reported a number of T-DM1 studies." "We look forward to the detail data when they are reported at a medical Conference", Daniel Junius, President and CEO.

On Trastuzumab Emtansine (T-DM1)

Trastuzumab Emtansine (the generic or international proprietary name for T-DM1) uses ImmunoGen's targeted antibodies payload (TAP) technology with the Trastuzumab antibody of Genentech developed. The connection is in the global development Roche under a cooperation agreement between ImmunoGen and Genentech.

T-DM1 is in the phase III trial for second-line and first-line treatment of HER2 positive MBC. A phase II study to evaluate the safety of T-DM1 in the neoadjuvant/adjuvanten started end of 2010.

References

1 E. Pérez et al., ESMO Congress 2010, abstract LBA3

Source:
ImmunoGen, Inc.

See drug information on Herceptin.